Vimarsana
Biggest News Aggregation in the World

Page 26 - While Covid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from While Covid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In While Covid Today - Breaking & Trending Today

How WPP's Move to Digital Could Boost the Ad Agency's Stock - Vimarsana News

How WPP's Move to Digital Could Boost the Ad Agency's Stock

Order Reprints Print Article Covid-19 has accelerated a move by clients to digital platforms, which will be a strength for WPP and its stock. Benjamin Fathers/AFP/Getty Images Text size The world’s largest advertising agency, WPP, is seen as a bellwether for the economic health of different sectors because marketing budgets tend to be axed first in tough times—and dusted off first when things pick up. The company, which counts Ford Motor and L’Oréal as clients, duly crashed about 22% over the past year during the pandemic as clients looked to cut cos...

The science on Ivermectin for Covid-19: Preliminary data is not enough, much more evidence is needed - Vimarsana News

The science on Ivermectin for Covid-19: Preliminary data is not enough, much more evidence is needed

One of these potential drugs, which is increasingly being promoted, is ivermectin, an  antiparasitic  Sufficient evidence is, however, currently lacking, although accelerated efforts to test ivermectin in humans are ongoing The Covid-19 vaccines have taken centre stage in the race to end the pandemic. However, vaccine rollout will take a long time before it covers the entire global population. In the meantime, scientists are looking to develop other targeted therapies for the disease, caused by SARS-CoV-2. One drug that has gained particular interest within the last couple of months is iver...

Source: news24.com
Ajanta Pharma's reasonable valuations and other factors that make it this week's stock pick - Vimarsana News

Ajanta Pharma's reasonable valuations and other factors that make it this week's stock pick

ET Invest NEWS Powered by Synopsis Ajanta Pharma beat street expectations in the second quarter of 2020-21. However, it is still valued reasonably compared to other mid cap pharma companies. Its fast growing US business and branded generics business in Africa will be the key growth drivers. While Covid helped a section of pharma companies, a lot of other companies suffered as patients postponed treatments for their noncritical illnesses. Ajanta Pharma fell in the secon,d category, since a major part of its revenue comes from areas like dermatology and opht...

Hospitals told to free up every possible bed for a coming surge of Covid patients - Vimarsana News

Hospitals told to free up every possible bed for a coming surge of Covid patients

Hospitals have been told to free up every possible bed for growing numbers of Covid patients as it emerged that Boxing Day was one of the London Ambulance Service’s busiest ever days. NHS England has warned that the entire health service will have to stay on its highest state of alert until at least the end of March due to an ongoing influx of patients. In a letter to local NHS bosses on Wednesday, the service’s chief operating officer Amanda Pritchard urged hospitals to mobilise their ‘surge capacity’ as they face soaring infections, staff sickness and longer patient stays.

Beat the Street in 2021 by betting on this midcap pharma stock - Vimarsana News

Beat the Street in 2021 by betting on this midcap pharma stock

Beat the Street in 2021 by betting on this midcap pharma stock Synopsis Ajanta Pharma beat street expectations in the second quarter of 2020-21. However, it is still valued reasonably compared to other mid cap pharma companies. Its fast growing US business and branded generics business in Africa will be the key growth drivers. While Covid helped a section of pharma companies, a lot of other companies suffered as patients postponed treatments for their noncritical illnesses. Ajanta Pharma fell in the secon,d category, since a major part of its revenue comes from areas like dermatology and opht...